{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:42:50Z","timestamp":1788478970500,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["21153MFDS607"],"award-info":[{"award-number":["21153MFDS607"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C1233"],"award-info":[{"award-number":["HI19C1233"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jmii.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T17:10:59Z","timestamp":1683047459000},"page":"842-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study"],"prefix":"10.1016","volume":"56","author":[{"given":"Ju Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-0941","authenticated-orcid":false,"given":"Han Eol","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5457-5780","authenticated-orcid":false,"given":"Seung Hun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-5109","authenticated-orcid":false,"given":"Hyunjin","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2023.04.009_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/cid\/ciy727","article-title":"Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study","volume":"68","author":"Zhao","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2023.04.009_bib5","series-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment - Drug-resistant tuberculosis treatment","article-title":"WHO guidelines approved by the guidelines review committee","year":"2020"},{"key":"10.1016\/j.jmii.2023.04.009_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00311-2017","article-title":"Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use","volume":"50","author":"Hafkin","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00017-2018","article-title":"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa","volume":"51","author":"Mohr","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","article-title":"A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity","volume":"117","author":"Patel","year":"2019","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jmii.2023.04.009_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5588\/ijtld.15.0541","article-title":"Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis","volume":"19","author":"Gupta","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5588\/ijtld.11.0591","article-title":"Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome","volume":"16","author":"Keshavjee","year":"2012","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2023.04.009_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.05.00006205","article-title":"High hepatotoxicity of pyrazinamide and ethambutol for\u00a0treatment of latent tuberculosis","volume":"26","author":"Younossian","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib17","series-title":"Global tuberculosis report 2021","year":"2021"},{"key":"10.1016\/j.jmii.2023.04.009_bib18","doi-asserted-by":"crossref","first-page":"e2018036","DOI":"10.4178\/epih.e2018036","article-title":"Tuberculosis control in the Republic of Korea","volume":"40","author":"Cho","year":"2018","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.jmii.2023.04.009_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib20","series-title":"Korea centers for disease Control and prevention. Korean guidelines for tuberculosis - fourth edition","year":"2020"},{"key":"10.1016\/j.jmii.2023.04.009_bib21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/cid\/ciab304","article-title":"Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid","volume":"73","author":"Hwang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology"},{"key":"10.1016\/j.jmii.2023.04.009_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jmii.2023.04.009_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method\u00a0of classifying prognostic comorbidity in longitudinal studies:\u00a0Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib27","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jmii.2023.04.009_bib28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41598-017-01213-5","article-title":"Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2023.04.009_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106336","article-title":"Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: a systematic review and meta-analysis","volume":"182","author":"Wu","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jmii.2023.04.009_bib30","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2023.04.009_bib31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tube.2014.04.001","article-title":"Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls","volume":"94","author":"Kakkar","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jmii.2023.04.009_bib32","first-page":"677","article-title":"Profile of delamanid for the treatment of multidrug-resistant tuberculosis","volume":"9","author":"Szumowski","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jmii.2023.04.009_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.jmii.2023.04.009_bib37","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized\u00a0for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2023.04.009_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jmii.2023.04.009_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","article-title":"Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French national health insurance database","volume":"32","author":"Billioti de Gage","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jmii.2023.04.009_bib40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2023.04.009_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad051","article-title":"Analysis of dynamic efficacy endpoints of the Nix-TB trial","author":"Solans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2023.04.009_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5588\/ijtld.18.0658","article-title":"Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-2015","volume":"23","author":"Lee","year":"2019","journal-title":"Int J Tubercul Lung Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:29:18Z","timestamp":1761658158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118223000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1684118223000877"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2023.04.009","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}